Continuing Medical Education Program - Purchase Exams
The purpose of The Medical Letter Continuing Medical Education Program is to provide a means for health care professionals (including physicians, physician assistants, nurse practitioners, and pharmacists) to keep up to date with new drugs that are approved by the FDA, as well as keep up with the recommended drug treatment for specific indications. Specifically, the content of The Medical Letter Continuing Medical Education Program covers the mechanisms of action, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and dosages of the drugs discussed. Participants are required to answer exam questions based on the content of The Medical Letter On Drugs and Therapeutics. Importantly, the objectives of developing the content on which the exam is based are to educate the participants, impact clinical practice, and improve patient outcomes. The Medical Letter's unbiased content is free of commercial influence and financial sponsorship. Our CME program is completely funded by fees paid by the exam participants. The Medical Letter Continuing Medical Education program is accredited by: ACCME, ABIM MOC, AAFP, AAPA, and ACPE.

  The Medical Letter Individual Exams — Online Only
I would like to order the following Online Per Issue Individual Exams eligible for 2 credits each: $15
per exam
1552  Drugs for Rheumatoid Arthritis (2 credits)   Expires 07/30/2019
1553  Sunscreens; Biktarvy - Another INSTI-Based Combination for HIV; Ciprofloxacin Otic Suspension (Otiprio) for Acute Otitis Externa; More Fluoroquinolone Warnings (2 credits)   Expires 08/13/2019
1554  Management of Opioid Withdrawal Symptoms; Two New Intra-Articular Injections for Knee Osteoarthritis (2 credits)
1555  Roxybond - An Abuse-Deterrent Formulation of Immediate-Release Oxycodone; Imvexxy - Another Estradiol Vaginal Insert for Dyspareunia; Osmolex ER - Another Extended-Release Amantadine for Parkinson’s Disease; Obiltoxaximab (Anthim) for Inhalational Anthrax; A Mometasone-Eluting Sinus Implant (Sinuva) for Nasal Polyps (2 credits)
1556  Antiviral Drugs for Varicella-Zoster Virus and Herpes Simplex Virus Infections; Hydrogen Peroxide 40% (Eskata) for Seborrheic Keratoses; Elagolix (Orilissa) - An Oral GnRH Antagonist for Endometriosis Pain (2 credits)
1557  Choice of Contraceptives (2 credits)
1558  Influenza Vaccine for 2018-2019; Tezacaftor/Ivacaftor (Symdeko) for Cystic Fibrosis; OTC Brimonidine (Lumify) for Ocular Redness (2 credits)
1559  Fremanezumab (Ajovy) and Galcanezumab (Emgality) for Migraine Prevention; Plazomicin (Zemdri) - A New Aminoglycoside Antibiotic; Cannabidiol (Epidiolex) for Epilepsy (2 credits)
1560  Vaccines for Travelers (2 credits)
1561  Baloxavir Marboxil (Xofluza) for Treatment of Influenza; Rivaroxaban (Xarelto) plus Aspirin for Secondary Prevention of Cardiovascular Events; Sodium Zirconium Cyclosilicate (Lokelma) for Hyperkalemia; Angiotensin II (Giapreza) for Septic Shock (2 credits)
1562  Drugs for Chronic Insomnia; Drugs for Cough (2 credits)
1563  Antiviral Drugs for Treatment and Prophylaxis of Seasonal Influenza; Tildrakizumab (Ilumya) - Another IL-23 Antagonist for Psoriasis; Dupilumab (Dupixent) for Asthma (2 credits)
1564  OTC Primatene Mist Returns; Qbrexza - A Glycopyrronium Cloth for Axillary Hyperhidrosis; Plenvu - A Low-Volume PEG-Based Colonoscopy Preparation; Revefenacin (Yupelri) for COPD; Aripiprazole with Digital Ingestion Tracking (Abilify MyCite) (2 credits)
1565  Lipid-Lowering Drugs (2 credits)
1566  An Epinephrine Prefilled Syringe (Symjepi) for Anaphylaxis; Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes; Fostamatinib (Tavalisse) for ITP; Oxybutynin for Hot Flashes in Women with Breast Cancer; Drug Interaction: Opioids and Oral P2Y12 Platelet Inhibitors (2 credits)
1567  Drugs for Gout; Xyosted - A Testosterone Auto-Injector for Hypogonadism; Rifamycin (Aemcolo) for Treatment of Travelers' Diarrhea (2 credits)
1568  ZTlido - A New Lidocaine Patch for Postherpetic Neuralgia; Sarecycline (Seysara) - Another Oral Tetracycline for Acne; Sulfonamide Cross-Reactivity; Desmopressin (Nocdurna and Noctiva) for Nocturnal Polyuria (2 credits)
1569  Drugs for Chronic Heart Failure; Esketamine Nasal Spray (Spravato) for Treatment-Resistant Depression (2 credits)
1570  OTC Drugs for Seasonal Allergies; Eravacycline (Xerava) - An IV Tetracycline for Complicated Intra-Abdominal Infections; Ozenoxacin 1% Cream (Xepi) for Impetigo (2 credits)
1571  Insulins for Type 2 Diabetes; Brexanolone (Zulresso) for Postpartum Depression; Siponimod (Mayzent) - A New Drug for Multiple Sclerosis; Tegaserod (Zelnorm) Returns (2 credits)
1572  Inhaled Levodopa (Inbrija) for Parkinson's Disease; Omadacycline (Nuzyra) - A New Tetracycline Antibiotic; Emicizumab (Hemlibra) for Subcutaneous Prophylaxis in Hemophilia A; PrabotulinumtoxinA (Jeuveau) for Frown Lines (2 credits)
1573  Risankizumab (Skyrizi) for Psoriasis; Romosozumab (Evenity) for Postmenopausal Osteoporosis; Prucalopride (Motegrity) for Chronic Idiopathic Constipation (2 credits)
1574  Drugs for Psoriasis (2 credits)
1575  Colorectal Cancer Screening; Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms; Tafenoquine (Arakoda and Krintafel) for Malaria (2 credits)
1576  Drugs for Smoking Cessation; Benzhydrocodone/Acetaminophen (Apadaz) for Pain (2 credits)